NAYA Biosciences (NAYA) 10-K 31 Mar 22 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-39701
Entity Registrant Name	INVO BIOSCIENCE, INC.
Entity Central Index Key	0001417926
Entity Tax Identification Number	20-4036208
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	5582 Broadcast Court
Entity Address, City or Town	Sarasota
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	34240
City Area Code	(978)
Local Phone Number	878-9505
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	INVO
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 46,939,332
Entity Common Stock, Shares Outstanding		12,089,298
Documents Incorporated by Reference	None.
ICFR Auditor Attestation Flag	false
Auditor Firm ID	2738
Auditor Name	M&K CPAS, PLLC
Auditor Location	Houston, TX

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash	$ 5,684,871	$ 10,097,760
Accounts receivable	50,470	21,699
Inventory	287,773	265,372
Prepaid expenses and other current assets	282,751	157,700
Total current assets	6,305,865	10,542,531
Property and equipment, net	501,436	132,206
Intangible assets, net	132,093	94,963
Lease right of use	2,037,052	79,319
Other assets		240
Investment in joint ventures	1,489,934	98,084
Total assets	10,466,380	10,947,343
Current liabilities
Accounts payable and accrued liabilities	443,422	328,927
Accrued compensation	581,689	527,326
Deferred revenue, current portion	5,900	714,286
Lease liability, current portion	221,993	22,707
Notes payable – Payroll Protection Program		157,620
Convertible notes, net		536,063
Income taxes payable		1,062
Total current liabilities	1,253,004	2,287,991
Lease liability, net of current portion	1,901,557	58,634
Deferred revenue, net of current portion		2,857,143
Deferred tax liability	1,139	469
Total liabilities	3,155,700	5,204,237
Stockholders’ equity
Common Stock, $.0001 par value; 125,000,000 shares authorized; 11,929,147 and 9,639,268 issued and outstanding as of December 31, 2021, and 2020, respectively	1,193	964
Additional paid-in capital	46,200,509	37,978,224
Accumulated deficit	(38,891,022)	(32,236,082)
Total stockholders’ equity	7,310,680	5,743,106
Total liabilities and stockholders’ equity	$ 10,466,380	$ 10,947,343

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock shares authorized	125,000,000	125,000,000
Common stock shares issued	11,929,147	9,639,268
Common stock shares outstanding	11,929,147	9,639,268

Consolidated statements of Oper

Consolidated statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue:
Total revenue	$ 4,160,116	$ 1,037,286
Cost of goods sold:
Production costs	126,326	79,035
Depreciation	18,726	9,725
Total cost of goods sold	145,052	88,760
Gross profit	4,015,064	948,526
Operating expenses
Selling, general and administrative expenses	9,015,158	6,065,066
Research and development expenses	216,430	398,426
Total operating expenses	9,231,588	6,463,492
Loss from operations	(5,216,524)	(5,514,966)
Other income (expense):
Loss from equity method joint ventures	(327,542)
Gain on extinguishment of debt	159,126
Interest income	3,657	4,190
Interest expense	(1,265,359)	(2,836,504)
Foreign currency exchange loss	(3,534)
Total other expenses	(1,433,652)	(2,832,314)
Net loss before income taxes	(6,650,176)	(8,347,280)
Income taxes	4,764	36
Net loss	$ (6,654,940)	$ (8,347,316)
Net loss per common share:
Basic	$ (0.63)	$ (1.52)
Diluted	$ (0.63)	$ (1.52)
Weighted average number of common shares outstanding:
Basic	10,632,413	5,489,738
Diluted	10,632,413	5,489,738
Product Revenue [Member]
Revenue:
Total revenue	$ 544,942	$ 323,000
Clinic Revenue [Member]
Revenue:
Total revenue	43,745
License Revenue [Member]
Revenue:
Total revenue	$ 3,571,429	$ 714,286

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficiency) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances at Dec. 31, 2019	$ 489	$ 20,174,682	$ (23,888,766)	$ (3,713,595)
Balance, shares at Dec. 31, 2019	4,884,879
Proceeds from the sale of common stock, net of offering costs	$ 416	11,474,636		11,475,052
Proceeds from the sale of common stock, net of offering costs, shares	4,153,750
Common stock issued to directors and employees	$ 11	465,129		465,140
Common stock issued to directors and employees, shares	112,056
Common stock issued to service providers	$ 3	150,859		150,862
Common stock issued to service providers, shares	34,751
Conversion of notes payable and accrued interest	$ 45	1,451,779		1,451,824
Conversion of notes payable and accrued interest, shares	453,699
Discount on convertible notes payables		3,120,150		3,120,150
Stock options issued to directors and employees as compensation		1,140,989		1,140,989
Rounding shares as a result of stock split
Rounding shares as a result of stock split, shares	133
Net income (loss)			(8,347,316)	(8,347,316)
Balances at Dec. 31, 2020	$ 964	37,978,224	(32,236,082)	5,743,106
Balance, shares at Dec. 31, 2020	9,639,268
Common stock issued to directors and employees	$ 5	360,148		360,153
Common stock issued to directors and employees, shares	49,806
Common stock issued for services	$ 24	804,100		804,124
Common stock issued for services, shares	237,750
Conversion of notes payable and accrued interest	$ 47	1,493,741		1,493,788
Conversion of notes payable and accrued interest, shares	466,809
Proceeds from the sale of common stock, net of offering costs	$ 124	3,650,573		3,650,697
Proceeds from the sale of common stock, net of offering costs, shares	1,240,737
Proceeds from warrant exercise	$ 4	123,558		123,562
Proceeds from warrant exercise, shares	39,095
Proceeds from unit purchase option exercise	$ 8	246,270		246,278
Proceeds from unit purchase option exercise, shares	77,444
Cashless warrant exercise	$ 9	(9)
Cashless warrant exercise, shares	91,709
Cashless unit purchase option exercise	$ 8	(8)
Cashless unit purchase option exercise, shares	86,529
Stock options issued to directors and employees as compensation		1,543,912		1,543,912
Net income (loss)			(6,654,940)	(6,654,940)
Balances at Dec. 31, 2021	$ 1,193	$ 46,200,509	$ (38,891,022)	$ 7,310,680
Balance, shares at Dec. 31, 2021	11,929,147

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (6,654,940)	$ (8,347,316)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash stock compensation issued for services	804,124	150,862
Non-cash stock compensation issued to directors and employees	360,153	465,140
Fair value of stock options issued to employees	1,543,912	1,140,989
Amortization of discount on notes payable	1,188,310	2,494,236
Debt conversion expense		131,984
Amortization of leasehold right of use asset	138,322	22,564
Gain on extinguishment of debt	(159,126)
Loss from equity method investment	327,542
Depreciation and amortization	27,760	11,917
Changes in assets and liabilities:
Accounts receivable	(28,771)	(14,141)
Inventory	(22,401)	(163,985)
Prepaid expenses and other current assets	(124,811)	38,210
Accounts payable and accrued expenses	114,495	(42,603)
Accrued compensation	54,363	134,309
Deferred revenue	(3,565,529)	(714,286)
Leasehold liability	(53,846)	(21,518)
Accrued interest	20,921	(61,696)
Income taxes payable	(392)	150
Deferred tax liabilities		36
Net cash used in operating activities	(6,029,914)	(4,775,148)
Cash from investing activities:
Payments to acquire property, plant, and equipment	(415,710)	(49,261)
Payments to acquire intangible assets	(38,939)	(39,669)
Other assets		(240)
Investment in joint ventures	(1,698,863)	(98,084)
Net cash used in investing activities	(2,153,512)	(187,254)
Cash from financing activities:
Proceeds from the sale of notes payable		2,998,905
Proceeds from the sale of common stock, net of offering costs	3,650,697	11,475,052
Proceeds from notes payable		157,620
Proceeds from warrant exercise	123,562
Proceeds from unit purchase option exercise	246,278
Principal payment on notes payable – related parties		(40,000)
Principal payment on notes payable	(250,000)	(770,000)
Net cash provided by financing activities	3,770,537	13,821,577
(Decrease) increase in cash and cash equivalents	(4,412,889)	8,859,175
Cash and cash equivalents at beginning of period	10,097,760	1,238,585
Cash and cash equivalents at end of period	5,684,871	10,097,760
Supplemental disclosure of cash flow information:
Interest	52,603	253,392
Taxes	3,307	1,062
Noncash activities:
Common stock issued upon note payable and accrued interest conversion	1,493,788	1,451,824
Cashless exercise of warrants	9
Cashless exercise of unit purchase options	8
Initial ROU asset and lease liability	2,096,055
Fair value of options issued for debt		524,452
Fair value of warrants issued with debt		524,452
Fair value of warrants issued related to service providers		8,660
Beneficial conversion feature on convertible notes		2,062,586
Fixed assets transferred to investment in joint venture	$ 20,529

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 1 – Summary of Significant Accounting Policies Description of Business INVO Bioscience, Inc. (“INVO” or the “Company”) is a commercial-stage fertility dedicated to expanding the assisted reproductive technology (“ART”) marketplace by making fertility care accessible and inclusive to people around the world. The Company’s flagship product is INVOcell, a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The Company’s primary mission is to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care. This treatment solution is the world’s first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as “IVC,” provides patients a more natural and intimate experience in comparison to other ART treatments. The IVC procedure can deliver comparable results at a lower cost than traditional in vitro The Company formed on January 5, 2007, under the laws of the Commonwealth of Massachusetts under the name Bio X Cell, Inc. to acquire the assets of Medelle Corporation (“Medelle”). Dr. Claude Ranoux purchased all of the assets of Medelle, and then he contributed those assets, including four patents relating to the INVOcell technology, to Bio X Cell, Inc. upon its formation in January 2007. On December 5, 2008, Bio X Cell, Inc., doing business as INVO Bioscience, and each of the shareholders of INVO Bioscience entered into a share exchange agreement and consummated a share exchange with Emy’s Salsa AJI Distribution Company, Inc., a Nevada corporation (“Emy’s”). Upon the closing of the share exchange on December 5, 2008, the INVO Bioscience shareholders transferred all of their shares of common stock in INVO Bioscience to Emy’s. In connection with the share exchange, Emy’s changed its name to INVO Bioscience, Inc. and Bio X Cell, Inc. became a wholly owned subsidiary of Emy’s (re-named INVO Bioscience, Inc.). Basis of Presentation The accompanying consolidated financial statements present on a consolidated basis the accounts of the Company and its wholly owned subsidiaries and controlled affiliates. The Company presents noncontrolling interest within the equity section of its consolidated balance sheets and the amount of consolidated net income (loss) that is attributable to the Company and to the noncontrolling interest in its consolidated statement of operations. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company uses the equity method of accounting when it owns an interest in an entity whereby it can exert significant influence over but cannot control the entity’s operations. The preparation of the Company’s consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. The Company considers events or transactions that have occurred after the consolidated balance sheet date of December 31, 2021, but prior to the filing of the consolidated financial statements with the SEC in this Annual Report on Form 10-K, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure, as applicable. Subsequent events have been evaluated through the date of the filing of this Annual Report on Form 10-K. Business Segments The Company operates in one Variable Interest Entities The Company’s consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and variable interest entities (“VIE”), where the Company is the primary beneficiary under the provisions of ASC 810, Consolidation (“ASC 810”). A VIE must be consolidated by its primary beneficiary when, along with its affiliates and agents, the primary beneficiary has both: (i) the power to direct the activities that most significantly impact the VIE’s economic performance; and (ii) the obligation to absorb losses or the right to receive the benefits of the VIE that could potentially be significant to the VIE. The Company reconsiders whether an entity is still a VIE only upon certain triggering events and continually assesses its consolidated VIEs to determine if it continues to be the primary beneficiary. See “Note 3 – Variable Interest Entities” for additional information on the Company’s VIEs. Equity Method Investments Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. Equity method investments are initially recorded at cost. These investments are included in investment in joint ventures in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments is reported in loss from equity method joint venture in the accompanying consolidated statements of operations. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the investees and records reductions in carrying values when necessary. Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Cash and Cash Equivalents For financial statement presentation purposes, the Company considers time deposits, certificates of deposit and all highly liquid investments with original maturities of three months or less to be cash and cash equivalents. At times, cash and cash equivalents balances exceed amounts insured by the Federal Deposit Insurance Corporation. Inventory Inventories consist of raw materials, work in process and finished goods and are stated at the lower of cost or net realizable value, using the first-in, first-out method as a cost flow method. Property and Equipment The Company records property and equipment at cost. Property and equipment is depreciated using the straight-line method over the estimated economic lives of the assets, which are from 3 10 Long- Lived Assets Long-lived assets and certain identifiable assets related to those assets are periodically reviewed for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. If the non-discounted future cash flows of the asset are less than their carrying amount, their carrying amounts are reduced to the fair value and an impairment loss recognized. There was no Fair Value of Financial Instruments ASC 825-10-50, “Disclosures about Fair Value of Financial Instruments,” requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. Effective January 1, 2008, the Company adopted ASC 820-10, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 requires that valuation techniques maximize the use of observable inputs and minimize the use of unobservable inputs. Income Taxes The Company is subject to income taxes in the United States and its domestic tax liabilities are subject to the allocation of expenses in multiple state jurisdictions. The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The recoverability of deferred tax assets is evaluated by assessing the adequacy of future expected taxable income from all sources, including taxable income in prior carryback years, reversal of taxable temporary differences, forecasted operating earnings and available tax planning strategies. To the extent the Company does not consider it more-likely-than-not that a deferred tax asset will be recovered, a valuation allowance is established. Business Segments The Company operates in one segment and therefore segment information is not presented. Concentration of Credit Risk Cash includes amounts deposited in financial institutions in excess of insurable Federal Deposit Insurance Corporation (“FDIC”) limits. As of December 31, 2021, the Company had cash balances in excess of FDIC limits. Revenue Recognition The Company recognizes revenue on arrangements in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services ASC 606 requires companies to assess their contracts to determine the timing and amount of revenue to recognize under the new revenue standard. The model has a five-step approach: 1. Identify the contract with the customer. 2. Identify the performance obligations in the contract. 3. Determine the total transaction price. 4. Allocate the total transaction price to each performance obligation in the contract. 5. Recognize as revenue when (or as) each performance obligation is satisfied. Revenue generated from the sale of INVOcell is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. Revenue generated from clinical and lab services related at the Company’s affiliated INVO Centers is typically recognized at the time the service is performed. On November 12, 2018, the Company entered into a U.S. Distribution Agreement (the “Ferring Agreement”) with Ferring International Center S.A. (“Ferring”), pursuant to which it granted Ferring an exclusive license in the United States market only, with rights to sublicense under patents related to our proprietary intravaginal culture device (INVOcell), together with the retention device and any other applicable accessories (collectively, the “Licensed Product”) to market, promote, distribute and sell the Licensed Product with respect to all therapeutic, prophylactic and diagnostic uses of medical devices or pharmaceutical products involving reproductive technology (including fertility treatment) in humans. On November 2, 2021, Ferring notified the Company of its intention to terminate the Ferring Agreement, which requires 90-days prior written notice. Accordingly, the Ferring Agreement officially terminated on January 31, 2022. The Ferring license was deemed to be a functional license that provides a customer with a “right to access” to the Company’s intellectual property during the subscription period and accordingly, under ASC 606-10-55-60 revenue is recognized over a period of time, which is generally the subscription period. The initial upfront payment of $ 5,000,000 7 As of December 31, 2021, the Company had no deferred revenue related to the Ferring Agreement as it was recognized in the fourth quarter of fiscal year 2021 in relation to the contract termination. Per ASC 606-10-55-48 the likelihood of Ferring exercising its rights became remote at the time notice of termination was received so INVO recognized the full remaining amount of the deferred revenue. Stock Based Compensation The Company accounts for stock-based compensation under the provisions of Accounting Standards Codification (“ASC”) subtopic 718-10, Compensation (“ASC 718-10”). This statement requires the Company to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period in which the employee is required to provide service or based on performance goals in exchange for the award, which is usually the vesting period. Loss Per Share Basic loss per share calculations are computed by dividing net loss attributable to the Company’s common shareholders by the weighted-average number of common shares outstanding. Diluted earnings per share are computed similar to basic earnings per share except that the denominator is increased to include potentially dilutive securities. The Company’s diluted loss per share is the same as the basic loss per share for the years ended December 31, 2021, and 2020, as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. Schedule of Earnings Per Share Basic and Diluted 2021 2020 Year Ended December 31, 2021 2020 Net loss (numerator) $ (6,654,940 ) $ (8,347,316 ) Basic and diluted weighted-average number of common shares outstanding (denominator) 10,632,413 5,489,738 Basic and diluted net loss per common share (0.63 ) (1.52 ) The Company has excluded the following dilutive securities from the calculation of fully diluted shares outstanding because the result would have been anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2021 2020 As of December 31, 2021 2020 Options 1,055,894 594,114 Convertible notes and interest - 536,302 Unit purchase options and warrants 260,165 613,996 Total 1,316,059 1,744,412 Recently Adopted Accounting Pronouncements The Company has reviewed all recently issued, but not yet effective, accounting pronouncements, and does not believe the future adoption of any such pronouncements will have a material impact on its financial condition or the results of its operations.

Liquidity

Liquidity	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity	Note 2 – Liquidity Historically, the Company has funded its cash and liquidity needs through operating cash flow, equity financings, and convertible notes. For the years ended December 31, 2021 and 2020, the Company incurred a net loss of approximately $ 6.7 million and $ 8.3 million, respectively, and has an accumulated deficit of approximately $ 38.9 million as of December 31, 2021. Approximately $ 4.2 million of the net loss was related to non-cash expenses for the year ended December 31, 2021, compared to $ 4.4 million for the year ended December 31, 2020. The Company has been dependent on raising capital from debt and equity financings to meet its needs for cash flow used in operating and investing activities. During 2020, the Company raised approximately $ 13.8 3.7 1.5 0.4 Although the Company’s audited financial statements for the year ended December 31, 2021 were prepared under the assumption that it would continue operations as a going concern, the report of the Company’s independent registered public accounting firm that accompanies the Company’s financial statements for the year ended December 31, 2021 contains a going concern qualification in which such firm expressed substantial doubt about the Company’s ability to continue as a going concern, based on the financial statements at that time. Specifically, as noted above, the Company has incurred significant operating losses and the Company expects to continue to incur significant expenses and operating losses as it continues to ramp up the commercialization of INVOcell and develop new INVO Centers. These prior losses and expected future losses have had, and will continue to have, an adverse effect on the Company’s financial condition. If the Company cannot continue as a going concern, its stockholders would likely lose most or all of their investment in the Company.

Variable Interest Entities

Variable Interest Entities	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	Note 3 – Variable Interest Entities Consolidated VIEs Bloom INVO, LLC On June 28, 2021, INVO CTR entered into a limited liability company agreement (the “Bloom Agreement”) with Bloom Fertility, LLC (“Bloom”) to establish a joint venture entity, formed as “Bloom INVO LLC” (the “Georgia JV”), for the purposes of commercializing INVOcell, and the related IVC procedure, through the establishment of an INVO Center, (the “Atlanta Clinic”) in the Atlanta, Georgia metropolitan area. In consideration for INVO’s commitment to contribute up to $ 800,000 800 1,200,000 1,200 The responsibilities of Bloom include providing all medical services required for the operation of the Atlanta Clinic. The responsibilities of INVO CTR include providing certain funding to the Georgia JV, lab services quality management, and providing access to and being the exclusive provider of the INVOcell to the Georgia JV. INVO CTR will also perform all required, industry specific compliance and accreditation functions, and product documentation for product registration. The Bloom Agreement provides Bloom with a “profits interest” in the Georgia JV and, in connection with such profits interest, states that profits and losses be allocated to its members based on a hypothetical liquidation of the Georgia JV. In such a scenario, liquidation proceeds would be distributed in the following order: (a) to INVO CTR until the difference between its capital contributions and distributions (the “Hurdle Amount”) equals $0; (b) to Bloom until its distributions equal 150 The Georgia JV opened to patients on September 7, 2021, and commenced initial treatment cycles in November 2021. The Company determined the Georgia JV is a VIE, and that the Company is its primary beneficiary because the Company has an obligation to absorb losses that are potentially significant and the Company controls the majority of the activities that impact the Georgia JV’s economic performance, specifically control of the INVOcell and lab services quality management. As a result, the Company consolidated the Georgia JV’s results with its own. As of December 31, 2021, the Company invested $ 0.5 million in the Georgia JV in the form of capital contributions as well as $ 0.5 million in the form of a note. For the year ended December 31, 2021, the Georgia JV recorded a net loss of $ 0.4 million. Noncontrolling interest in the Georgia JV was $ 0 . Unconsolidated VIEs HRCFG INVO, LLC On March 10, 2021, INVO CTR entered into a limited liability company agreement with HRCFG, LLC (“HRCFG”) to form a joint venture for the purpose of establishing an INVO Center in Birmingham, Alabama. The name of the joint venture entity is HRCFG INVO, LLC (the “Alabama JV”). The Company also provides certain funding to the Alabama JV. Each party owns 50 The Alabama JV opened to patients on August 9, 2021, and initial treatment cycles commenced in September 2021. The Company determined the Alabama JV is a VIE, and that there is no primary beneficiary. As a result, the Company will use the equity method to account for its interest in the Alabama JV. As of December 31, 2021, the Company invested $ 1.7 million in the Alabama JV in the form of a note. For the year ended December 31, 2021, the Alabama JV recorded a net loss of $ 0.6 million of which the Company recognized a loss from equity method investment of $ 0.3 million. Positib Fertility, S.A. de C.V. On September 24, 2020, INVO CTR entered into a Pre-Incorporation and Shareholders Agreement with Francisco Arredondo, MD PLLC (“Arredondo”) and Security Health LLC, a Texas limited liability company (“Ramirez”, and together with INVO CTR and Arredondo, the “Shareholders”) under which the Shareholders will commercialize the IVC procedure and offer related medical treatments in Mexico. Each party owns one-third of the Mexican incorporated company, Positib Fertility, S.A. de C.V. (the “Mexico JV”). The Mexico JV opened to patients on November 1, 2021, and commenced initial treatment cycles beginning in January 2022. The Company determined the Mexico JV is a VIE, and that there is no primary beneficiary. As a result, the Company will use the equity method to account for its interest in the Mexico JV. As of December 31, 2021, the Company invested $ 0.1 0.04 million of which the Company recognized a loss from equity method investment of $ 0.01 million. The following table summarizes our investments in unconsolidated VIEs: Schedule of Investments in Unconsolidated Variable Interest Entities Carrying Value as of Location Percentage Ownership December 31, 2021 December 31, 2020 HRCFG INVO, LLC Alabama, United States 50 % $ 1,387,495 - Positib Fertility, S.A. de C.V. Mexico 33 % 102,439 - Total investment in unconsolidated VIEs $ 1,489,934 - Earnings from investments in unconsolidated VIEs were as follows: Schedule of Earnings from Investments in Unconsolidated Variable Interest Entities 2021 2020 Year Ended December 31, 2021 2020 HRCFG INVO, LLC $ (313,033 ) - Positib Fertility, S.A. de C.V. (14,509 ) - Total earnings from unconsolidated VIEs $ (327,542 ) - The following tables summarize the combined unaudited financial information of our investments in unconsolidated VIEs: Schedule of Financial Information of Investments in Unconsolidated Variable Interest Entities 2021 2020 Year Ended December 31, 2021 2020 Statements of operations: Operating revenue $ 151,672 - Operating expenses (821,705 ) - Net loss $ (670,033 ) - December 31, 2021 December 31, 2020 Balance sheets: Current assets $ 456,967 - Long-term assets 1,302,067 - Current liabilities (404,155 ) - Long-term liabilities (142,321 ) - Net assets $ 1,212,558 -

Agreements and Transactions wit

Agreements and Transactions with VIE’s	12 Months Ended
	Dec. 31, 2021
Agreements And Transactions With Vies
Agreements and Transactions with VIE’s	Note 4 – Agreements and Transactions with VIE’s The Company sells the INVOcell to its consolidated and unconsolidated VIEs and anticipates continuing to do so in the ordinary course of business. All intercompany transactions with consolidated entities are eliminated in the Company’s consolidated financial statements. Per ASC 323-10-35-8 the Company eliminates any sales to an unconsolidated VIE for INVOcell inventory that the VIE still has remaining on the books at period end. The following table summarizes the Company’s transactions with VIEs: Summary of Transaction with Variable Interest Entities \ 2021 2020 Year Ended December 31, 2021 2020 Bloom Invo, LLC INVOcell revenue $ 21,600 - Unconsolidated VIEs INVOcell revenue $ 16,310 - The Company had balances with VIEs as follows: Summary of Balances with Variable Interest Entities December 31,2021 December 31, 2020 Bloom Invo, LLC Accounts receivable $ 21,600 - Notes payable 453,406 - Unconsolidated VIEs Accounts receivable $ 16,310 -

Inventory

Inventory	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventory	Note 5 – Inventory Components of inventory are: Schedule of Inventory December 31, 2021 December 31, 2020 Raw materials $ 67,605 $ 72,022 Work in process - 29,645 Finished goods 220,168 163,705 Total inventory $ 287,773 $ 265,372

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 6 – Property and Equipment The estimated useful lives and accumulated depreciation for equipment are as follows as of December 31, 2021, and December 31, 2020: Schedule of Esimated Useful Lives of Property and Equipment Estimated Useful Life Manufacturing equipment 6 10 Medical equipment 10 Office equipment 3 7 Schedule of Property and Equipment December 31, 2021 December 31, 2020 Manufacturing equipment $ 132,513 $ 132,513 Medical equipment 275,423 49,261 Office equipment 74,891 2,689 Leasehold improvements 96,817 - Less: accumulated depreciation (78,208 ) (52,257 ) Total equipment, net $ 501,436 $ 132,206 During each of the years ended December 31, 2021, and 2020, the Company recorded depreciation expense of $ 25,952 10,110

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 7 – Intangible Assets Components of intangible assets are as follows: Schedule of Finite-Lived Intangible Assets December 31, 2021 December 31, 2020 Trademarks $ 110,842 $ 89,536 Patents 95,355 77,722 Accumulated amortization (74,104 ) (72,295 ) Total patent costs, net $ 132,093 $ 94,963 The Company capitalizes the initial expense related to establishing patents by country and then amortizes the expense over the life of the patent, typically 20 years. It then expenses annual filing fees to maintain the patents. The Company regularly reviews the value of its patents in the marketplace in proportion to the expense it must spend to maintain the patent. During the years ended December 31, 2021, and 2020, the Company recorded amortization expenses related to patents of $ 1,809 1,807 The trademarks have an indefinite life and therefore are not amortized. Trademarks are periodically reviewed for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. The trademark assets were created in 2019, and no material adverse changes have occurred since their creation.

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases
Leases	Note 9 – Leases The Company has various operating lease agreements in place for its office and joint ventures. Per FASB’s ASU 2016-02, Leases Topic 842 (“ASU 2016-02”), effective January 1, 2019, the Company is required to report a right-of-use asset and corresponding liability to report the present value of the total lease payments, with appropriate interest calculation. Per the terms of ASU 201-02, the Company can use its implicit interest rate, if known, or applicable federal rate otherwise. Since the Company’s implicit interest rate was not readily determinable, the Company utilized the applicable federal rate, as of the commencement of the lease. Lease renewal options included in any lease are considered in the lease term if it is reasonably certain the Company will exercise the option to renew. The Company’s operating lease agreements do not contain any material restrictive covenants. As of December 31, 2021, the Company’s lease components included in the consolidated balance sheet were as follows: Schedule of Lease Components Lease component Balance sheet classification December 31, Assets ROU assets - operating lease Other assets $ 2,037,052 Total ROU assets $ 2,037,052 Liabilities Current operating lease liability Current liabilities $ 221,993 Long-term operating lease liability Other liabilities 1,901,557 Total lease liabilities $ 2,123,550 Future minimum lease payments as of December 31, 2021 were as follows: Schedule of Future Minimum Lease Payments 2022 $ 258,406 2023 264,108 2024 251,671 2025 247,960 2026 and beyond 1,316,245 Total future minimum lease payments $ 2,338,390 Less: Interest (214,840 ) Total operating lease liabilities $ 2,123,550

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Notes Payable	Note 10 – Notes Payable 2020 Convertible Notes Payable From May 15, 2020, through July 1, 2020, the Company entered into agreements with accredited investors for their purchase of secured convertible notes issued by the Company in the aggregate original principal amount of $ 3,494,840 (the “2020 Convertible Notes”). See Note 14 – Unit Purchase Options and Warrants for additional information on related securities. Interest on the 2020 Convertible Notes accrued at a rate of 10 % per annum and was payable on the maturity dates of November 15, 2021, December 22, 2021, and December 30, 2021 . All amounts of principal and interest due under the 2020 Convertible Notes were convertible at any time after the issuance date, in whole or in part (subject to rounding for fractional shares), at the option of the holders, into the Company’s common stock at a fixed conversion price of $ 3.20 As of December 31, 2021, all 2020 Convertible Notes had either converted or been repaid by the Company. Principal balances of the 2020 Convertible Notes were as follows: Schedule of Convertible Notes December 31, 2021 December 31, 2020 2020 Convertible Notes - 1,700,000 Accrued interest - 24,373 Less beneficial conversion feature discount - (604,897 ) Less options discount - (224,051 ) Less warrants discount - (229,954 ) Less issuance cost - (129,408 ) Total, net of discount $ - $ 536,063 Interest expense on the 2020 Convertible Notes was $ 72,018 194,631 Amortization of options discount on the 2020 Convertible Notes was $ 224,051 300,365 Amortization of warrant discount on the 2020 Convertible Notes was $ 229,954 301,228 Amortization of beneficial conversion feature on the 2020 Convertible Notes was $ 604,897 1,670,135 Amortization of issuance costs on the 2020 Convertible Notes was $ 129,408 222,508 Paycheck Protection Program On July 1, 2020, the Company received a loan in the principal amount of $ 157,620 pursuant to the U.S. Small Business Administration’s Paycheck Protection Program. The loan matured 18 months from the date of funding, was payable over 18 equal monthly installments, and had an interest of 1% per annum . Up to 100% of the principal balance of the loan was forgivable based upon satisfaction of certain criteria under the Paycheck Protection Program . On June 16, 2021, the principal of the loan as well as $ 1,506 of accrued interest was forgiven and the note was extinguished. The Company recognized a gain of $ 159,126 on extinguishment of debt during the year ended December 31, 2021.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 11 – Related Party Transactions In November 2020, Paulson Investment Company served as a co-managing underwriter for the Company’s underwritten public offering and received fees and commissions for such role in the amount of $ 271,440 In October 2021, Paulson Investment Company served as a placement agent for the Company’s registered direct offering and received fees and commissions for such role in the amount of $ 323,584 30,674 199,994

Stockholders_ Equity

Stockholders’ Equity	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Stockholders’ Equity	Note 12 – Stockholders’ Equity Reverse Stock Splits On December 16, 2019, the Company’s stockholders approved a reverse stock split at a ratio of between 1-for-5 and 1-for-25 1-for-20 1-for-20 On October 22, 2020, the Company’s board of directors approved a reverse stock split of the Company’s common stock at a ratio of 5-for-8 125,000,000 200,000,000 5-for-8 133 The consolidated financial statements presented reflect the reverse splits. Public offerings On November 12, 2020, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Roth Capital Partners, LLC, as representative of the several underwriters (the “Underwriters”), in connection with the Company’s public offering (the “Offering”) of 3,625,000 3.20 3,625,000 528,750 1.5 4,153,750 11.8 On October 1, 2021, the Company and certain institutional and accredited investors and members of the Company’s management team (the “Investors”) entered into a securities purchase agreement pursuant to which the Company agreed to issue and sell to the Investors 1,240,737 4,044,803 3.26 3.65 323,584 37,222 3.912 During the years ended December 31, 2021, and 2020, the Company incurred approximately $ 0.4 million and $ 1.8 million, respectively of offering costs related to the issuance of common stock. Year Ended December 30, 2021 During 2021, the Company issued 466,809 shares of common stock with a fair value of $ 1,493,788 as a result of the conversion of the 2020 Convertible Notes and accrued interest thereon. No gain or loss was recorded on conversion, as the issuance of common stock was pursuant to the terms of a prior agreement. In March 2021, the Company issued 77,444 246,278 In March 2021, the Company issued 39,095 123,562 In March 2021, the Company issued 86,529 In March 2021, the Company issued 91,709 During 2021, the Company issued 49,806 shares of common stock to employees and directors and 110,250 shares of common stock to consultants with a fair value of $ 360,153 and $ 382,645 , respectively. The shares were issued under the Company’s 2019 Stock Incentive Plan (the “2019 Plan”). During 2021, the Company issued 97,500 shares of its common stock to consultants in consideration of services rendered with a fair value of $ 303,879 . These shares were issued pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended. The Company did not receive any cash proceeds from this issuance. In November 2021, the Company issued 30,000 117,600

Equity-Based Compensation

Equity-Based Compensation	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Equity-Based Compensation	Note 13 – Equity-Based Compensation Equity Incentive Plans In October 2019, the Company adopted the 2019 Plan. Under the 2019 Plan, the Company’s board of directors is authorized to grant both incentive and non-qualified stock options to purchase common stock, as well as restricted stock awards to its employees, directors, and consultants. The 2019 Plan initially provided for the issuance of 500,000 A provision in the 2019 Plan provides for an automatic annual increase equal to 6% of the total number of shares of Company common stock outstanding on December 31 of the preceding calendar year. In January 2020, the number of available shares was increased to 793,093 578,356 1,371,449 Options granted under the 2019 Plan generally have a life of 3 10 three-year The following table sets forth the activity of the options to purchase common stock under the 2019 Plan. Schedule of Stock Options Activity Number of Weighted Aggregate Outstanding as of December 31, 2020 939,114 $ 5.73 $ 17,250 Granted 179,797 3.14 - Exercised - - - Canceled (63,017 ) 9.10 - Balance as of December 31, 2021 1,055,894 $ 5.09 $ 133,022 Exercisable as of December 31, 2021 650,161 $ 5.71 $ 54,266 The fair value of each option granted is estimated as of the grant date using the Black-Scholes option pricing model with the following assumptions: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Years ended 2021 2020 Risk-free interest rate range 0.22 % to 0.73 % 0.48% to 1.65 % Expected life of option-years 5.3 6.5 5.20 5.77 Expected stock price volatility 107 % to 125 % 111% to 128. % Expected dividend yield - % - % The risk-free interest rate is based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the stock options. Expected volatility is based upon the average historical volatility of the Company’s common stock over the period commensurate with the expected term of the related instrument. The expected life and estimated post-employment termination behavior is based upon historical experience of homogeneous groups, executives and non-executives, within the Company. The Company does not currently pay dividends on its common stock, nor does it expect to do so in the foreseeable future. Schedule of Share Based Payments Arrangements Options Exercised and Options Vested Total Intrinsic Total Fair Year ended December 31, 2020 $ - $ 1,495,744 Year ended December 31, 2021 $ - $ 1,543,912 For the year ended December 31, 2021, the weighted average grant date fair value of options granted was $ 3.14 per share. The Company estimates the fair value of options at the grant date using the Black-Scholes model. For all stock options granted through December 31, 2021, the weighted average remaining service period is 4.0 years. Restricted Stock and Restricted Stock Units In the year ended December 31, 2021, the Company issued 198,063 shares of restricted stock to certain employees, directors, and consultants under the 2019 Plan. Restricted stock issued to employees, directors, and consultants generally vest either at grant or vest over a period of one year from the date of grant . The following table summarizes the Company’s restricted stock awards activity under the 2019 Plan during the year ended December 31, 2021: Schedule of Aggregate Restricted Stock Awards and Restricted Stock Unit Activity Number of Unvested Shares Weighted Average Grant Date Aggregate Value of Shares Balance as of December 31, 2020 16,698 $ 4.67 $ 77,927 Granted 198,063 3.29 652,098 Vested (205,031 ) 3.27 (693,877 ) Forfeitures - - - Balance as of December 31, 2021 9,730 $ 3.72 $ 36,148

Unit Purchase Options and Warra

Unit Purchase Options and Warrants	12 Months Ended
	Dec. 31, 2021
Unit Purchase Options And Warrants
Unit Purchase Options and Warrants	Note 14 – Unit Purchase Options and Warrants In connection with the issuance of the 2020 Convertible Notes, the Company also issued unit purchase options to purchase 303,623 3.20 one 3.20 five years In connection with the issuance of the 2020 Convertible Notes, the Company agreed to issue the placement agent and the selling agent five 6,750 3.20 A Monte Carlo model was used because the investor unit purchase options and warrants contain fundamental transaction payouts and reset events that cannot be modeled with a Black Scholes model. The fair value of the unit purchase options and warrants issued to the convertible debt holders is estimated as of the issue date using a Monte Carlo model with the following assumptions: Schedule of Fair Value Measurement Inputs and Valuation Techniques Risk-free interest rate range 0.33 0.39 % Stock price $ 3.00 3.95 Expected life of warrants and unit purchase options (years) 5.00 Expected stock price volatility 108.2 112.5 % Expected dividend yield 0 % The risk-free interest rate is based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the unit purchase options and warrants. Expected volatility is based upon the historical volatility of the Company’s common stock over the period commensurate with the expected term of the related instrument. The unit purchase options and warrants are valued assuming projected reset events adjusting the exercise price and a forced exercise upon a projected fundamental transaction by management. The unit purchase options and warrants early exercise are modeled assuming registration after 180 days. The Company does not currently pay dividends on its common stock, nor does it expect to in the foreseeable future. The following table sets forth the activity of unit purchase options: Schedule of Unit Purchase Stock Options Activity Number of Weighted Aggregate Outstanding as of December 31, 2020 303,623 $ 3.20 $ - Granted - - - Exercised (210,730 ) 3.20 457,839 Canceled - - - Balance as of December 31, 2021 92,893 $ 3.20 $ 5,647 The following table sets forth the activity of warrants: Schedule of Warrants Activity Number of Weighted Aggregate Outstanding as of December 31, 2020 310,373 $ 3.48 $ - Granted 37,222 3.91 - Exercised (180,323 ) 3.20 457,839 Canceled - - - Balance as of December 31, 2021 167,272 $ 3.62 $ 16,029

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 15 – Income Taxes The provision for income taxes consists of the following for the year ended December 31, 2021, and 2020: Schedule of Components of Income Tax Expense (Benefit) 2021 2020 December 31 2021 2020 Federal income taxes: Current - - Deferred 280 (84 ) Total federal income taxes 280 (84 ) State income taxes: Current 4,094 1,212 Deferred 390 120 Total state income taxes 4,484 1,332 Total income taxes $ 4,764 $ 1,248 The effective income tax rate is lower than the U.S. federal and state statutory rates primarily because of the valuation allowance and, to a lesser extent, permanent items. A reconciliation of the 2021 and 2020 federal statutory rate as compared to the effective income tax rate is as follows: Schedule of Effective Income Tax Rate Reconciliation December 31 2021 2020 Pre-Tax Book Income at Statutory Rate $ (1,363,829 ) 21.00 % $ (1,688,606 ) 21.00 % State Tax Expense, net 3,624 - 0.06 % 1,078 - 0.01 % Permanent Items 425,318 - 6.55 % 37,441 - 0.47 % True-Ups 713,398 - 10.98 % 6,790 - 0.09 % Change in Federal Valuation Allowance 226,255 - 3.48 % 1,644,545 - 20.45 % Total Expense $ 4,764 - 0.07 % $ 1,248 - 0.02 % Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax. Significant components of the deferred tax assets and liabilities as of December 31, 2021 and 2020, are as follows: Schedule of Deferred Tax Assets and Liabilities 2021 2020 December 31 2021 2020 Deferred tax assets: Accrued Compensation $ 150,952 $ 127,829 Amortization of Discount Notes Payable - 93,017 Lease (ASC 842) 365,602 19,718 Charitable Contributions 136 127 Stock Option Expense 75,590 28,212 Restricted Stock Unit 12,929 10,665 Deferred Revenue - 865,747 Net Operating Losses 6,406,223 5,361,500 Org Costs 72,455 - Investment in HRCFG INVO, LLC 81,234 - Equity in earnings - Positib 3,765 - Gross deferred tax assets 7,168,886 6,506,815 Deferred tax liabilities: Fixed Assets (26,907 ) (32,159 ) ROU Lease (ASC 842) (353,551 ) (19,228 ) Trademark Amortization (4,309 ) (1,529 ) Convertible Note Interest Expense - (42,111 ) Note Issuance Cost - (3,855 ) Gross deferred tax liability (384,767 ) (98,882 ) Less: valuation allowance (6,785,258 ) (6,408,401 ) Net deferred tax liability $ (1,139 ) $ (468 ) The Company recorded a full valuation allowance against its net deferred tax asset at December 31, 2021 and 2020 totaling $ 6.8 million and $ 6.4 million , respectively. A naked credit resulting from indefinite lived intangibles was valued at December 31, 2021, and 2020 totaling ($1,139 ) and ($468 ), respectively. As of December 31, 2021, the Company has federal net operating loss carryforwards of approximately $ 25.8 10.8 15.0 23.5 3.5 20.0

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 16 – Commitments and Contingencies Insurance The Company’s insurance coverage is carried with third-party insurers and includes: (i) general liability insurance covering third-party exposures; (ii) statutory workers’ compensation insurance; (iv) excess liability insurance above the established primary limits for general liability and automobile liability insurance; (v) property insurance, which covers the replacement value of real and personal property and includes business interruption; and (vi) insurance covering our directors and officers for acts related to our business activities. All coverage is subject to certain limits and deductibles, the terms and conditions of which are common for companies with similar types of operations. Legal Matters The Company is not currently subject to any material legal proceedings; however, it could be subject to legal proceedings and claims from time to time in the ordinary course of its business, or legal proceedings it considered immaterial may in the future become material. Regardless of the outcome, litigation can, among other things, be time consuming and expensive to resolve, and can divert management resources.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 17 – Subsequent Events In January 2022, the Company issued 62,528 In February 2022, the Company issued 3,000 In January 2022, the Company issued 94,623 315,000 On March 29, 2022, the joint venture agreement between the Company and Medesole Healthcare and Trading Private Limited, India was terminated by the Company pursuant to the terms of the joint venture agreement after mutual agreement with Medesole that Medesole would not be able to fulfil its commitments in a timely fashion.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Description of Business	Description of Business INVO Bioscience, Inc. (“INVO” or the “Company”) is a commercial-stage fertility dedicated to expanding the assisted reproductive technology (“ART”) marketplace by making fertility care accessible and inclusive to people around the world. The Company’s flagship product is INVOcell, a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The Company’s primary mission is to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care. This treatment solution is the world’s first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as “IVC,” provides patients a more natural and intimate experience in comparison to other ART treatments. The IVC procedure can deliver comparable results at a lower cost than traditional in vitro The Company formed on January 5, 2007, under the laws of the Commonwealth of Massachusetts under the name Bio X Cell, Inc. to acquire the assets of Medelle Corporation (“Medelle”). Dr. Claude Ranoux purchased all of the assets of Medelle, and then he contributed those assets, including four patents relating to the INVOcell technology, to Bio X Cell, Inc. upon its formation in January 2007. On December 5, 2008, Bio X Cell, Inc., doing business as INVO Bioscience, and each of the shareholders of INVO Bioscience entered into a share exchange agreement and consummated a share exchange with Emy’s Salsa AJI Distribution Company, Inc., a Nevada corporation (“Emy’s”). Upon the closing of the share exchange on December 5, 2008, the INVO Bioscience shareholders transferred all of their shares of common stock in INVO Bioscience to Emy’s. In connection with the share exchange, Emy’s changed its name to INVO Bioscience, Inc. and Bio X Cell, Inc. became a wholly owned subsidiary of Emy’s (re-named INVO Bioscience, Inc.).
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements present on a consolidated basis the accounts of the Company and its wholly owned subsidiaries and controlled affiliates. The Company presents noncontrolling interest within the equity section of its consolidated balance sheets and the amount of consolidated net income (loss) that is attributable to the Company and to the noncontrolling interest in its consolidated statement of operations. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company uses the equity method of accounting when it owns an interest in an entity whereby it can exert significant influence over but cannot control the entity’s operations. The preparation of the Company’s consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. The Company considers events or transactions that have occurred after the consolidated balance sheet date of December 31, 2021, but prior to the filing of the consolidated financial statements with the SEC in this Annual Report on Form 10-K, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure, as applicable. Subsequent events have been evaluated through the date of the filing of this Annual Report on Form 10-K.
Business Segments	Business Segments The Company operates in one
Variable Interest Entities	Variable Interest Entities The Company’s consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and variable interest entities (“VIE”), where the Company is the primary beneficiary under the provisions of ASC 810, Consolidation (“ASC 810”). A VIE must be consolidated by its primary beneficiary when, along with its affiliates and agents, the primary beneficiary has both: (i) the power to direct the activities that most significantly impact the VIE’s economic performance; and (ii) the obligation to absorb losses or the right to receive the benefits of the VIE that could potentially be significant to the VIE. The Company reconsiders whether an entity is still a VIE only upon certain triggering events and continually assesses its consolidated VIEs to determine if it continues to be the primary beneficiary. See “Note 3 – Variable Interest Entities” for additional information on the Company’s VIEs.
Equity Method Investments	Equity Method Investments Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. Equity method investments are initially recorded at cost. These investments are included in investment in joint ventures in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments is reported in loss from equity method joint venture in the accompanying consolidated statements of operations. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the investees and records reductions in carrying values when necessary.
Use of Estimates	Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents For financial statement presentation purposes, the Company considers time deposits, certificates of deposit and all highly liquid investments with original maturities of three months or less to be cash and cash equivalents. At times, cash and cash equivalents balances exceed amounts insured by the Federal Deposit Insurance Corporation.
Inventory	Inventory Inventories consist of raw materials, work in process and finished goods and are stated at the lower of cost or net realizable value, using the first-in, first-out method as a cost flow method.
Property and Equipment	Property and Equipment The Company records property and equipment at cost. Property and equipment is depreciated using the straight-line method over the estimated economic lives of the assets, which are from 3 10
Long- Lived Assets	Long- Lived Assets Long-lived assets and certain identifiable assets related to those assets are periodically reviewed for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. If the non-discounted future cash flows of the asset are less than their carrying amount, their carrying amounts are reduced to the fair value and an impairment loss recognized. There was no
Fair Value of Financial Instruments	Fair Value of Financial Instruments ASC 825-10-50, “Disclosures about Fair Value of Financial Instruments,” requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. Effective January 1, 2008, the Company adopted ASC 820-10, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 requires that valuation techniques maximize the use of observable inputs and minimize the use of unobservable inputs.
Income Taxes	Income Taxes The Company is subject to income taxes in the United States and its domestic tax liabilities are subject to the allocation of expenses in multiple state jurisdictions. The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The recoverability of deferred tax assets is evaluated by assessing the adequacy of future expected taxable income from all sources, including taxable income in prior carryback years, reversal of taxable temporary differences, forecasted operating earnings and available tax planning strategies. To the extent the Company does not consider it more-likely-than-not that a deferred tax asset will be recovered, a valuation allowance is established.
Business Segments	Business Segments The Company operates in one segment and therefore segment information is not presented.
Concentration of Credit Risk	Concentration of Credit Risk Cash includes amounts deposited in financial institutions in excess of insurable Federal Deposit Insurance Corporation (“FDIC”) limits. As of December 31, 2021, the Company had cash balances in excess of FDIC limits.
Revenue Recognition	Revenue Recognition The Company recognizes revenue on arrangements in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services ASC 606 requires companies to assess their contracts to determine the timing and amount of revenue to recognize under the new revenue standard. The model has a five-step approach: 1. Identify the contract with the customer. 2. Identify the performance obligations in the contract. 3. Determine the total transaction price. 4. Allocate the total transaction price to each performance obligation in the contract. 5. Recognize as revenue when (or as) each performance obligation is satisfied. Revenue generated from the sale of INVOcell is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. Revenue generated from clinical and lab services related at the Company’s affiliated INVO Centers is typically recognized at the time the service is performed. On November 12, 2018, the Company entered into a U.S. Distribution Agreement (the “Ferring Agreement”) with Ferring International Center S.A. (“Ferring”), pursuant to which it granted Ferring an exclusive license in the United States market only, with rights to sublicense under patents related to our proprietary intravaginal culture device (INVOcell), together with the retention device and any other applicable accessories (collectively, the “Licensed Product”) to market, promote, distribute and sell the Licensed Product with respect to all therapeutic, prophylactic and diagnostic uses of medical devices or pharmaceutical products involving reproductive technology (including fertility treatment) in humans. On November 2, 2021, Ferring notified the Company of its intention to terminate the Ferring Agreement, which requires 90-days prior written notice. Accordingly, the Ferring Agreement officially terminated on January 31, 2022. The Ferring license was deemed to be a functional license that provides a customer with a “right to access” to the Company’s intellectual property during the subscription period and accordingly, under ASC 606-10-55-60 revenue is recognized over a period of time, which is generally the subscription period. The initial upfront payment of $ 5,000,000 7 As of December 31, 2021, the Company had no deferred revenue related to the Ferring Agreement as it was recognized in the fourth quarter of fiscal year 2021 in relation to the contract termination. Per ASC 606-10-55-48 the likelihood of Ferring exercising its rights became remote at the time notice of termination was received so INVO recognized the full remaining amount of the deferred revenue.
Stock Based Compensation	Stock Based Compensation The Company accounts for stock-based compensation under the provisions of Accounting Standards Codification (“ASC”) subtopic 718-10, Compensation (“ASC 718-10”). This statement requires the Company to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period in which the employee is required to provide service or based on performance goals in exchange for the award, which is usually the vesting period.
Loss Per Share	Loss Per Share Basic loss per share calculations are computed by dividing net loss attributable to the Company’s common shareholders by the weighted-average number of common shares outstanding. Diluted earnings per share are computed similar to basic earnings per share except that the denominator is increased to include potentially dilutive securities. The Company’s diluted loss per share is the same as the basic loss per share for the years ended December 31, 2021, and 2020, as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. Schedule of Earnings Per Share Basic and Diluted 2021 2020 Year Ended December 31, 2021 2020 Net loss (numerator) $ (6,654,940 ) $ (8,347,316 ) Basic and diluted weighted-average number of common shares outstanding (denominator) 10,632,413 5,489,738 Basic and diluted net loss per common share (0.63 ) (1.52 ) The Company has excluded the following dilutive securities from the calculation of fully diluted shares outstanding because the result would have been anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2021 2020 As of December 31, 2021 2020 Options 1,055,894 594,114 Convertible notes and interest - 536,302 Unit purchase options and warrants 260,165 613,996 Total 1,316,059 1,744,412
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements The Company has reviewed all recently issued, but not yet effective, accounting pronouncements, and does not believe the future adoption of any such pronouncements will have a material impact on its financial condition or the results of its operations.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Earnings Per Share Basic and Diluted	Schedule of Earnings Per Share Basic and Diluted 2021 2020 Year Ended December 31, 2021 2020 Net loss (numerator) $ (6,654,940 ) $ (8,347,316 ) Basic and diluted weighted-average number of common shares outstanding (denominator) 10,632,413 5,489,738 Basic and diluted net loss per common share (0.63 ) (1.52 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The Company has excluded the following dilutive securities from the calculation of fully diluted shares outstanding because the result would have been anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2021 2020 As of December 31, 2021 2020 Options 1,055,894 594,114 Convertible notes and interest - 536,302 Unit purchase options and warrants 260,165 613,996 Total 1,316,059 1,744,412

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Investments in Unconsolidated Variable Interest Entities	The following table summarizes our investments in unconsolidated VIEs: Schedule of Investments in Unconsolidated Variable Interest Entities Carrying Value as of Location Percentage Ownership December 31, 2021 December 31, 2020 HRCFG INVO, LLC Alabama, United States 50 % $ 1,387,495 - Positib Fertility, S.A. de C.V. Mexico 33 % 102,439 - Total investment in unconsolidated VIEs $ 1,489,934 -
Schedule of Earnings from Investments in Unconsolidated Variable Interest Entities	Earnings from investments in unconsolidated VIEs were as follows: Schedule of Earnings from Investments in Unconsolidated Variable Interest Entities 2021 2020 Year Ended December 31, 2021 2020 HRCFG INVO, LLC $ (313,033 ) - Positib Fertility, S.A. de C.V. (14,509 ) - Total earnings from unconsolidated VIEs $ (327,542 ) -
Schedule of Financial Information of Investments in Unconsolidated Variable Interest Entities	The following tables summarize the combined unaudited financial information of our investments in unconsolidated VIEs: Schedule of Financial Information of Investments in Unconsolidated Variable Interest Entities 2021 2020 Year Ended December 31, 2021 2020 Statements of operations: Operating revenue $ 151,672 - Operating expenses (821,705 ) - Net loss $ (670,033 ) - December 31, 2021 December 31, 2020 Balance sheets: Current assets $ 456,967 - Long-term assets 1,302,067 - Current liabilities (404,155 ) - Long-term liabilities (142,321 ) - Net assets $ 1,212,558 -

Agreements and Transactions w_2

Agreements and Transactions with VIE’s (Tables)	12 Months Ended
	Dec. 31, 2021
Agreements And Transactions With Vies
Summary of Transaction with Variable Interest Entities	The following table summarizes the Company’s transactions with VIEs: Summary of Transaction with Variable Interest Entities \ 2021 2020 Year Ended December 31, 2021 2020 Bloom Invo, LLC INVOcell revenue $ 21,600 - Unconsolidated VIEs INVOcell revenue $ 16,310 -
Summary of Balances with Variable Interest Entities	The Company had balances with VIEs as follows: Summary of Balances with Variable Interest Entities December 31,2021 December 31, 2020 Bloom Invo, LLC Accounts receivable $ 21,600 - Notes payable 453,406 - Unconsolidated VIEs Accounts receivable $ 16,310 -

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Schedule of Inventory	Components of inventory are: Schedule of Inventory December 31, 2021 December 31, 2020 Raw materials $ 67,605 $ 72,022 Work in process - 29,645 Finished goods 220,168 163,705 Total inventory $ 287,773 $ 265,372

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Esimated Useful Lives of Property and Equipment	The estimated useful lives and accumulated depreciation for equipment are as follows as of December 31, 2021, and December 31, 2020: Schedule of Esimated Useful Lives of Property and Equipment Estimated Useful Life Manufacturing equipment 6 10 Medical equipment 10 Office equipment 3 7
Schedule of Property and Equipment	Schedule of Property and Equipment December 31, 2021 December 31, 2020 Manufacturing equipment $ 132,513 $ 132,513 Medical equipment 275,423 49,261 Office equipment 74,891 2,689 Leasehold improvements 96,817 - Less: accumulated depreciation (78,208 ) (52,257 ) Total equipment, net $ 501,436 $ 132,206

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Components of intangible assets are as follows: Schedule of Finite-Lived Intangible Assets December 31, 2021 December 31, 2020 Trademarks $ 110,842 $ 89,536 Patents 95,355 77,722 Accumulated amortization (74,104 ) (72,295 ) Total patent costs, net $ 132,093 $ 94,963

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases
Schedule of Lease Components	As of December 31, 2021, the Company’s lease components included in the consolidated balance sheet were as follows: Schedule of Lease Components Lease component Balance sheet classification December 31, Assets ROU assets - operating lease Other assets $ 2,037,052 Total ROU assets $ 2,037,052 Liabilities Current operating lease liability Current liabilities $ 221,993 Long-term operating lease liability Other liabilities 1,901,557 Total lease liabilities $ 2,123,550
Schedule of Future Minimum Lease Payments	Future minimum lease payments as of December 31, 2021 were as follows: Schedule of Future Minimum Lease Payments 2022 $ 258,406 2023 264,108 2024 251,671 2025 247,960 2026 and beyond 1,316,245 Total future minimum lease payments $ 2,338,390 Less: Interest (214,840 ) Total operating lease liabilities $ 2,123,550

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Convertible Notes	Principal balances of the 2020 Convertible Notes were as follows: Schedule of Convertible Notes December 31, 2021 December 31, 2020 2020 Convertible Notes - 1,700,000 Accrued interest - 24,373 Less beneficial conversion feature discount - (604,897 ) Less options discount - (224,051 ) Less warrants discount - (229,954 ) Less issuance cost - (129,408 ) Total, net of discount $ - $ 536,063

Equity-Based Compensation (Tabl

Equity-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Schedule of Stock Options Activity	The following table sets forth the activity of the options to purchase common stock under the 2019 Plan. Schedule of Stock Options Activity Number of Weighted Aggregate Outstanding as of December 31, 2020 939,114 $ 5.73 $ 17,250 Granted 179,797 3.14 - Exercised - - - Canceled (63,017 ) 9.10 - Balance as of December 31, 2021 1,055,894 $ 5.09 $ 133,022 Exercisable as of December 31, 2021 650,161 $ 5.71 $ 54,266
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The fair value of each option granted is estimated as of the grant date using the Black-Scholes option pricing model with the following assumptions: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Years ended 2021 2020 Risk-free interest rate range 0.22 % to 0.73 % 0.48% to 1.65 % Expected life of option-years 5.3 6.5 5.20 5.77 Expected stock price volatility 107 % to 125 % 111% to 128. % Expected dividend yield - % - %
Schedule of Share Based Payments Arrangements Options Exercised and Options Vested	Schedule of Share Based Payments Arrangements Options Exercised and Options Vested Total Intrinsic Total Fair Year ended December 31, 2020 $ - $ 1,495,744 Year ended December 31, 2021 $ - $ 1,543,912
Schedule of Aggregate Restricted Stock Awards and Restricted Stock Unit Activity	The following table summarizes the Company’s restricted stock awards activity under the 2019 Plan during the year ended December 31, 2021: Schedule of Aggregate Restricted Stock Awards and Restricted Stock Unit Activity Number of Unvested Shares Weighted Average Grant Date Aggregate Value of Shares Balance as of December 31, 2020 16,698 $ 4.67 $ 77,927 Granted 198,063 3.29 652,098 Vested (205,031 ) 3.27 (693,877 ) Forfeitures - - - Balance as of December 31, 2021 9,730 $ 3.72 $ 36,148

Unit Purchase Options and War_2

Unit Purchase Options and Warrants (Tables)	12 Months Ended
	Dec. 31, 2021
Unit Purchase Options And Warrants
Schedule of Fair Value Measurement Inputs and Valuation Techniques	The fair value of the unit purchase options and warrants issued to the convertible debt holders is estimated as of the issue date using a Monte Carlo model with the following assumptions: Schedule of Fair Value Measurement Inputs and Valuation Techniques Risk-free interest rate range 0.33 0.39 % Stock price $ 3.00 3.95 Expected life of warrants and unit purchase options (years) 5.00 Expected stock price volatility 108.2 112.5 % Expected dividend yield 0 %
Schedule of Unit Purchase Stock Options Activity	The following table sets forth the activity of unit purchase options: Schedule of Unit Purchase Stock Options Activity Number of Weighted Aggregate Outstanding as of December 31, 2020 303,623 $ 3.20 $ - Granted - - - Exercised (210,730 ) 3.20 457,839 Canceled - - - Balance as of December 31, 2021 92,893 $ 3.20 $ 5,647
Schedule of Warrants Activity	The following table sets forth the activity of warrants: Schedule of Warrants Activity Number of Weighted Aggregate Outstanding as of December 31, 2020 310,373 $ 3.48 $ - Granted 37,222 3.91 - Exercised (180,323 ) 3.20 457,839 Canceled - - - Balance as of December 31, 2021 167,272 $ 3.62 $ 16,029

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit)	The provision for income taxes consists of the following for the year ended December 31, 2021, and 2020: Schedule of Components of Income Tax Expense (Benefit) 2021 2020 December 31 2021 2020 Federal income taxes: Current - - Deferred 280 (84 ) Total federal income taxes 280 (84 ) State income taxes: Current 4,094 1,212 Deferred 390 120 Total state income taxes 4,484 1,332 Total income taxes $ 4,764 $ 1,248
Schedule of Effective Income Tax Rate Reconciliation	The effective income tax rate is lower than the U.S. federal and state statutory rates primarily because of the valuation allowance and, to a lesser extent, permanent items. A reconciliation of the 2021 and 2020 federal statutory rate as compared to the effective income tax rate is as follows: Schedule of Effective Income Tax Rate Reconciliation December 31 2021 2020 Pre-Tax Book Income at Statutory Rate $ (1,363,829 ) 21.00 % $ (1,688,606 ) 21.00 % State Tax Expense, net 3,624 - 0.06 % 1,078 - 0.01 % Permanent Items 425,318 - 6.55 % 37,441 - 0.47 % True-Ups 713,398 - 10.98 % 6,790 - 0.09 % Change in Federal Valuation Allowance 226,255 - 3.48 % 1,644,545 - 20.45 % Total Expense $ 4,764 - 0.07 % $ 1,248 - 0.02 %
Schedule of Deferred Tax Assets and Liabilities	Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax. Significant components of the deferred tax assets and liabilities as of December 31, 2021 and 2020, are as follows: Schedule of Deferred Tax Assets and Liabilities 2021 2020 December 31 2021 2020 Deferred tax assets: Accrued Compensation $ 150,952 $ 127,829 Amortization of Discount Notes Payable - 93,017 Lease (ASC 842) 365,602 19,718 Charitable Contributions 136 127 Stock Option Expense 75,590 28,212 Restricted Stock Unit 12,929 10,665 Deferred Revenue - 865,747 Net Operating Losses 6,406,223 5,361,500 Org Costs 72,455 - Investment in HRCFG INVO, LLC 81,234 - Equity in earnings - Positib 3,765 - Gross deferred tax assets 7,168,886 6,506,815 Deferred tax liabilities: Fixed Assets (26,907 ) (32,159 ) ROU Lease (ASC 842) (353,551 ) (19,228 ) Trademark Amortization (4,309 ) (1,529 ) Convertible Note Interest Expense - (42,111 ) Note Issuance Cost - (3,855 ) Gross deferred tax liability (384,767 ) (98,882 ) Less: valuation allowance (6,785,258 ) (6,408,401 ) Net deferred tax liability $ (1,139 ) $ (468 )

Schedule of Earnings Per Share

Schedule of Earnings Per Share Basic and Diluted (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Net loss (numerator)	$ (6,654,940)	$ (8,347,316)
Basic and diluted weighted-average number of common shares outstanding (denominator)	10,632,413	5,489,738
Basic and diluted net loss per common share	$ (0.63)	$ (1.52)

Schedule of Antidilutive Securi

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,316,059	1,744,412
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,055,894	594,114
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		536,302
Unit Purchase Option and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	260,165	613,996

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative)	Nov. 02, 2021USD ($)	Dec. 31, 2021USD ($)Segment	Dec. 31, 2020USD ($)
Property, Plant and Equipment [Line Items]
Number of operating segment | Segment		1
Impairment of intangible assets		$ 0	$ 0
Initial upfront payment	$ 5,000,000
Term of license	7 years
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment estimated useful life		3
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment estimated useful life		10

Liquidity (Details Narrative)

Liquidity (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net income loss	$ 6,654,940	$ 8,347,316
Accumulated deficit	38,891,022	32,236,082
Net income loss related to non-cash expenses	4,200,000	4,400,000
Debt and equity financing		13,800,000
Proceeds from sale of stock	$ 3,700,000
Outstaning debt		1,500,000
Proceeds from purchase option and warrants exercises		$ 400,000

Schedule of Investments in Unco

Schedule of Investments in Unconsolidated Variable Interest Entities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Investment in unconsolidated variable interest entities	$ 1,489,934
HRCFG INVO, LLC [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership Percentage	50.00%
Investment in unconsolidated variable interest entities	$ 1,387,495
Positib Fertility, S.A. de C.V. [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership Percentage	33.00%
Investment in unconsolidated variable interest entities	$ 102,439

Schedule of Earnings from Inves

Schedule of Earnings from Investments in Unconsolidated Variable Interest Entities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Total earnings from unconsolidated VIEs	$ (327,542)
HRCFG INVO, LLC [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Total earnings from unconsolidated VIEs	(313,033)
Positib Fertility, S.A. de C.V. [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Total earnings from unconsolidated VIEs	$ (14,509)

Schedule of Financial Informati

Schedule of Financial Information of Investments in Unconsolidated Variable Interest Entities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Operating revenue	$ (5,216,524)	$ (5,514,966)
Net loss	(6,654,940)	(8,347,316)
Current assets	6,305,865	10,542,531
Current liabilities	(1,253,004)	(2,287,991)
Variable Interest Entity, Primary Beneficiary [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Operating revenue	151,672
Operating expenses	(821,705)
Net loss	(670,033)
Current assets	456,967
Long-term assets	1,302,067
Current liabilities	(404,155)
Long-term liabilities	(142,321)
Net assets	$ 1,212,558

Variable Interest Entities (Det

Variable Interest Entities (Details Narrative) - USD ($)	Jun. 28, 2021	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Variable interest entity percentage	150.00%
Net income (loss)		$ (6,654,940)	$ (8,347,316)
Georgia JV [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investment		500,000
Notes receivable		500,000
Net income (loss)		400,000
Stockholders' Equity Attributable to Noncontrolling Interest		0
Alabama JV [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investment		1,700,000
Net income (loss)		600,000
Loss from equity investment		300,000
Mexico JV [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investment		100,000
Net income (loss)		40,000
Loss from equity investment		$ 10,000
Bloom invo LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Variable interest entirty commitment contribution	$ 1,200,000
Variable interest entity units issued	1,200
Bloom invo LLC [Member] | Bloom Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Variable interest entity units issued	800
Bloom invo LLC [Member] | Bloom Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Variable interest entirty commitment contribution	$ 800,000
Alabama JV [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Variable interest entity percentage	50.00%

Summary of Transaction with Var

Summary of Transaction with Variable Interest Entities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Consolidated Entity, Excluding VIE [Member] | Bloom invo LLC [Member]
INVOcell revenue	$ 21,600
Variable Interest Entity, Not Primary Beneficiary [Member]
INVOcell revenue	$ 16,310

Summary of Balances with Variab

Summary of Balances with Variable Interest Entities (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Consolidated Entity, Excluding VIE [Member] | Bloom invo LLC [Member]
Accounts receivable	$ 21,600
Notes payable	453,406
Variable Interest Entity, Not Primary Beneficiary [Member]
Accounts receivable	$ 16,310

Schedule of Inventory (Details)

Schedule of Inventory (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 67,605	$ 72,022
Work in process		29,645
Finished goods	220,168	163,705
Total inventory	$ 287,773	$ 265,372

Schedule of Esimated Useful Liv

Schedule of Esimated Useful Lives of Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Medical Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years	10 years
Minimum [Member] | Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	6 years	6 years
Minimum [Member] | Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	3 years	3 years
Maximum [Member] | Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years	10 years
Maximum [Member] | Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	7 years	7 years

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Less: accumulated depreciation	$ (78,208)	$ (52,257)
Total equipment, net	501,436	132,206
Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Leasehold improvements	132,513	132,513
Medical Equipment [Member]
Property, Plant and Equipment [Line Items]
Leasehold improvements	275,423	49,261
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Leasehold improvements	74,891	2,689
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Leasehold improvements	$ 96,817

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 25,952	$ 10,110

Schedule of Finite-Lived Intang

Schedule of Finite-Lived Intangible Assets (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Indefinite-lived Intangible Assets [Line Items]
Accumulated amortization	$ (74,104)	$ (72,295)
Total patent costs, net	132,093	94,963
Patents [Member]
Indefinite-lived Intangible Assets [Line Items]
Patents	95,355	77,722
Trademarks [Member]
Indefinite-lived Intangible Assets [Line Items]
Patents	$ 110,842	$ 89,536

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of Intangible Ass	$ 1,809	$ 1,807

Schedule of Lease Components (D

Schedule of Lease Components (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Leases
ROU assets - operating lease	$ 2,037,052	$ 79,319
Total ROU assets	2,037,052
Current operating lease liability	221,993	22,707
Long-term operating lease liability	1,901,557	$ 58,634
Total lease liabilities	$ 2,123,550

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments (Details)	Dec. 31, 2021USD ($)
Leases
2022	$ 258,406
2023	264,108
2024	251,671
2025	247,960
2026 and beyond	1,316,245
Total future minimum lease payments	2,338,390
Less: Interest	(214,840)
Total operating lease liabilities	$ 2,123,550

Schedule of Convertible Notes (

Schedule of Convertible Notes (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
2020 Convertible Notes		$ 1,700,000
Accrued interest		24,373
Less beneficial conversion feature discount		(604,897)
Less options discount		(224,051)
Less warrants discount		(229,954)
Less issuance cost		(129,408)
Total, net of discount		$ 536,063

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Jun. 16, 2021	Jul. 02, 2020	Dec. 31, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Debt Instrument, Face Amount				$ 1,500,000
Amortization of debt discount			$ 1,188,310	2,494,236
Paycheck Protection Program [Member]
Short-term Debt [Line Items]
Debt Instrument, Face Amount		$ 157,620
Debt Instrument, Maturity Date, Description		The loan matured 18 months from the date of funding, was payable over 18 equal monthly installments, and had an interest of 1% per annum
Debt Instrument, Description		Up to 100% of the principal balance of the loan was forgivable based upon satisfaction of certain criteria under the Paycheck Protection Program
Debt Instrument, Increase, Accrued Interest	$ 1,506
Extinguishment of debt			159,126
2020 Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Debt Instrument, Face Amount		$ 3,494,840
Debt Instrument, Interest Rate, Stated Percentage		10.00%
Debt Instrument, Maturity Date, Description		the maturity dates of November 15, 2021, December 22, 2021, and December 30, 2021
Conversion price		$ 3.20
Interest expense, debt			72,018	194,631
Amortization of debt discount			224,051	300,365
Amortization of warrant discount			229,954	301,228
Amortization of beneficial conversion feature			604,897	1,670,135
Amortization of debt issuance costs			$ 129,408	$ 222,508

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	1 Months Ended
	Oct. 31, 2021	Nov. 30, 2020
Chief Executive Officer and Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Number of shares issued	30,674
Proceeds from related party	$ 199,994
Director [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Amounts of Transaction	$ 323,584	$ 271,440

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)

Oct. 02, 2021

Nov. 20, 2020

Nov. 18, 2020

Nov. 17, 2020

Nov. 12, 2020

Nov. 05, 2020

Oct. 22, 2020

May 21, 2020

Feb. 19, 2020

Dec. 16, 2019

Nov. 30, 2021

Mar. 31, 2021

Dec. 31, 2021

Dec. 31, 2020

Subsidiary, Sale of Stock [Line Items]

Reverse stock split

5-for-8

Common Stock, Shares Authorized

125,000,000

125,000,000

Reverse stock splits, shares issued

133

Proceeds from Issuance of Common Stock

$ 3,650,697

$ 11,475,052

Stock Issued During Period, Value, Conversion of Convertible Securities

1,493,788

1,451,824

Proceeds from unit purchase option exercise

246,278

Proceeds from warrant exercise

123,562

Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture

360,153

465,140

Stock Issued During Period, Value, Issued for Services

804,124

Fair Value Of Common Stock

$ 3,650,697

Effortless IVF [Member]

Subsidiary, Sale of Stock [Line Items]

Number of shares issued

30,000

Fair Value Of Common Stock

$ 117,600

Warrants [Member]

Subsidiary, Sale of Stock [Line Items]

Proceeds from warrant exercise, shares

39,095

Proceeds from warrant exercise

$ 123,562

Cashless warrant exercise, shares

91,709

Options [Member]

Subsidiary, Sale of Stock [Line Items]

Proceeds from unit purchase option exercise, shares

77,444

Proceeds from unit purchase option exercise

$ 246,278

Cashless unit purchase option exercise, shares

86,529

2020 Convertible Notes Payable [Member]

Subsidiary, Sale of Stock [Line Items]

Stock Issued During Period, Shares, Conversion of Convertible Securities

466,809

Stock Issued During Period, Value, Conversion of Convertible Securities

$ 1,493,788

IPO [Member]

Subsidiary, Sale of Stock [Line Items]

Offering costs

$ 400,000

$ 1,800,000

IPO [Member] | Underwriting Agreement [Member]

Subsidiary, Sale of Stock [Line Items]

Number of shares issued

3,625,000

3,625,000

Share Price

$ 3.20

Stock Repurchased During Period, Shares

528,750

Proceeds from Issuance of Common Stock

$ 1,500,000

SaleOfStockNumberOfSharesIssuedInTransaction

4,153,750

Sale of Stock, Consideration Received on Transaction

$ 11,800,000

Board of Directors [Member]

Subsidiary, Sale of Stock [Line Items]

Reverse stock split

5-for-8

1-for-20

1-for-20

1-for-5 and 1-for-25

Common Stock, Shares Authorized

200,000,000

125,000,000

Investors [Member] | IPO [Member]

Subsidiary, Sale of Stock [Line Items]

SaleOfStockNumberOfSharesIssuedInTransaction

1,240,737

Sale of Stock, Consideration Received on Transaction

$ 4,044,803

Sale of Stock, Price Per Share

$ 3.26

Net proceeds from offering

$ 3,650,000

Debt Instrument, Fee

$ 323,584

Warrants to purchase shares

37,222

Sale of Stock, Price Per Share

$ 3.912

Employees and Directors [Member] | 2019 Stock Incentive Plan [Member]

Subsidiary, Sale of Stock [Line Items]

Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture

49,806

Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture

$ 360,153

Consultant [Member]

Subsidiary, Sale of Stock [Line Items]

Stock Issued During Period, Shares, Issued for Services

97,500

Stock Issued During Period, Value, Issued for Services

$ 303,879

Consultant [Member] | 2019 Stock Incentive Plan [Member]

Subsidiary, Sale of Stock [Line Items]

Stock Issued During Period, Shares, Issued for Services

110,250

Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture

$ 382,645

Schedule of Stock Options Activ

Schedule of Stock Options Activity (Details)	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Equity [Abstract]
Number of Shares, Options Outstanding, Beginning balance | shares	939,114
Weighted Average Exercise Price, Options Outstanding, Beginning balance | $ / shares	$ 5.73
Aggregate Intrinsic Value, Options Outstanding, Beginning balance | $	$ 17,250
Number of Shares, Options Outstanding, Granted | shares	179,797
Weighted Average Exercise Price, Options Outstanding, Granted | $ / shares	$ 3.14
Number of Shares, Options Outstanding, Exercised | shares
Weighted Average Exercise Price, Options Outstanding, Exercised | $ / shares
Number of Shares, Options Outstanding, Canceled | shares	(63,017)
Weighted Average Exercise Price, Options Outstanding, Canceled | $ / shares	$ 9.10
Number of Shares, Options Outstanding, Ending balance | shares	1,055,894
Weighted Average Exercise Price, Options Outstanding, Ending balance | $ / shares	$ 5.09
Aggregate Intrinsic Value, Options Outstanding, Ending balance | $	$ 133,022
Number of Shares, Options Exercisable, Ending balance | shares	650,161
Weighted Average Exercise Price, Options Exercisable, Ending balance | $ / shares	$ 5.71
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | $	$ 54,266

Schedule of Share-based Payment

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	0.22%	0.48%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	0.73%	1.65%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	107.00%	111.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	125.00%	128.00%
Expected dividend yield
Minimum [Member]
Expected life of option-years	5 years 3 months 18 days	5 years 2 months 12 days
Maximum [Member]
Expected life of option-years	6 years 6 months	5 years 9 months 7 days

Schedule of Share Based Payment

Schedule of Share Based Payments Arrangements Options Exercised and Options Vested (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Total Intrinsic Value of Options Exercised
Total Fair Value of Options Vested	$ 1,543,912	$ 1,495,744

Schedule of Aggregate Restricte

Schedule of Aggregate Restricted Stock Awards and Restricted Stock Unit Activity (Details)	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Equity [Abstract]
Number of Unvested Shares, Beginning balance | shares	16,698
Weighted Average Exercise Price, Beginning balance | $ / shares	$ 4.67
Aggregate Value of Unvested Shares, Beginning balance | $	$ 77,927
Number of Unvested Shares, Granted | shares	198,063
Weighted Average Exercise Price, Granted | $ / shares	$ 3.29
Aggregate Value of Unvested Shares, Granted | $	$ 652,098
Number of Unvested Shares, Vested | shares	(205,031)
Weighted Average Exercise Price, Vested | $ / shares	$ 3.27
Aggregate Value of Unvested Shares, Vested | $	$ (693,877)
Number of Unvested Shares, Forfeitures | shares
Weighted Average Exercise Price, Forfeitures | $ / shares
Aggregate Value of Unvested Shares, Forfeitures | $
Number of Unvested Shares, Ending balance | shares	9,730
Weighted Average Exercise Price, Ending balance | $ / shares	$ 3.72
Aggregate Value of Unvested Shares, Ending balance | $	$ 36,148

Equity-Based Compensation (Deta

Equity-Based Compensation (Details Narrative) - $ / shares	12 Months Ended
	Dec. 31, 2021	Jan. 31, 2020	Oct. 31, 2019
Share-based Payment Arrangement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 3.14
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	4 years
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	one year from the date of grant
Restricted Stock [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued shares of restricted stock	198,063
Restricted Stock [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued shares of restricted stock	198,063
Restricted Stock [Member] | Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued shares of restricted stock	198,063
2019 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based issuance of shares		1,371,449	500,000
Share based payment arrangement, description	A provision in the 2019 Plan provides for an automatic annual increase equal to 6% of the total number of shares of Company common stock outstanding on December 31 of the preceding calendar year. In January 2020, the number of available shares was increased to 793,093
Number of available shares issuable		578,356
Vesting period	three-year
2019 Stock Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options life	3 years
2019 Stock Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options life	10 years

Schedule of Fair Value Measurem

Schedule of Fair Value Measurement Inputs and Valuation Techniques (Details)	Dec. 31, 2021$ / shares
Measurement Input, Expected Term [Member]
Expected life of warrants and unit purchase options (years)	5 years
Measurement Input, Expected Dividend Rate [Member]
Warrants measurement input	0
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants measurement input	0.33
Minimum [Member] | Measurement Input, Share Price [Member]
Stock Price	$ 3
Minimum [Member] | Measurement Input, Price Volatility [Member]
Warrants measurement input	108.2
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants measurement input	0.39
Maximum [Member] | Measurement Input, Share Price [Member]
Stock Price	$ 3.95
Maximum [Member] | Measurement Input, Price Volatility [Member]
Warrants measurement input	112.5

Schedule of Unit Purchase Stock

Schedule of Unit Purchase Stock Options Activity (Details)	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Options Outstanding, Beginning balance | shares	939,114
Weighted Average Exercise Price, Options Outstanding, Beginning balance	$ 5.73
Aggregate Intrinsic Value, Options Outstanding, Beginning balance | $	$ 17,250
Number of unit purchase options, granted | shares	179,797
Weighted average exercise price, granted	$ 3.14
Number of unit purchase options, canceled | shares	63,017
Weighted average exercise price, canceled	$ 9.10
Number of Shares, Options Outstanding, Ending balance | shares	1,055,894
Weighted Average Exercise Price, Options Outstanding, Ending balance	$ 5.09
Aggregate Intrinsic Value, Options Outstanding, Ending balance | $	$ 133,022
Unit Purchase Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Options Outstanding, Beginning balance | shares	303,623
Weighted Average Exercise Price, Options Outstanding, Beginning balance	$ 3.20
Aggregate Intrinsic Value, Options Outstanding, Beginning balance | $
Number of unit purchase options, granted | shares
Weighted average exercise price, granted
Aggregate intrinsic value, granted
Number of unit purchase options, exercised | shares	(210,730)
Weighted average exercise price, exercised	$ 3.20
Aggregate intrinsic value, exercised | $	$ 457,839
Number of unit purchase options, canceled | shares
Weighted average exercise price, canceled
Aggregate intrinsic value, canceled
Number of Shares, Options Outstanding, Ending balance | shares	92,893
Weighted Average Exercise Price, Options Outstanding, Ending balance	$ 3.20
Aggregate Intrinsic Value, Options Outstanding, Ending balance | $	$ 5,647

Schedule of Warrants Activity (

Schedule of Warrants Activity (Details)	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Unit Purchase Options And Warrants
Number of warrants, outstanding, beginning balance | shares	310,373
Weighted average exercise price, outstanding, beginning balance | $ / shares	$ 3.48
Aggregate intrinsic value, outstanding, beginning balance | $
Number of warrants, granted | shares	37,222
Weighted average exercise price, granted | $ / shares	$ 3.91
Aggregate intrinsic value, granted | $
Number of warrants, exercised | shares	(180,323)
Weighted average exercise price, exercised | $ / shares	$ 3.20
Aggregate intrinsic value, exercised | $	$ 457,839
Number of warrants, canceled | shares
Weighted average exercise price, canceled | $ / shares
Aggregate intrinsic value, canceled | $
Number of warrants, outstanding, ending balance | shares	167,272
Weighted average exercise price, outstanding, ending balance | $ / shares	$ 3.62
Aggregate intrinsic value, outstanding, ending balance | $	$ 16,029

Unit Purchase Options and War_3

Unit Purchase Options and Warrants (Details Narrative) - 2020 Convertible Notes Payable [Member]	Dec. 31, 2021$ / sharesshares
Warrant [Member]
Warrants to pruchase | shares	1
Warrants exercise price | $ / shares	$ 3.20
Warrant term	5 years
Warrant [Member] | Tribal Capital Markets L L C [Member]
Warrants to pruchase | shares	6,750
Warrants exercise price | $ / shares	$ 3.20
Warrant term	5 years
Unit Purchase Options [Member]
Number of unit option issued | shares	303,623
Shares Issued, Price Per Share | $ / shares	$ 3.20

Schedule of Components of Incom

Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Current
Deferred	280	(84)
Total federal income taxes	280	(84)
Current	4,094	1,212
Deferred	390	120
Total state income taxes	4,484	1,332
Total income taxes	$ 4,764	$ 1,248

Schedule of Effective Income Ta

Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Pre-tax book income	$ (1,363,829)	$ (1,688,606)
Pre-tax book income	21.00%	21.00%
State Tax Expense, net	$ 3,624	$ 1,078
State Tax Expense, net	0.06%	0.01%
Permanent Items	$ 37,441	$ 425,318
Permanent Items	6.55%	0.47%
True-Ups	$ 713,398	$ 6,790
True-Ups	10.98%	0.09%
Valuation Allowance	$ 226,255	$ 1,644,545
Valuation Allowance	3.48%	20.45%
Total Expense	$ 4,764	$ 1,248
Total Expense	0.07%	0.02%

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Accrued Compensation	$ 150,952	$ 127,829
Amortization of Discount Notes Payable		93,017
Lease (ASC 842)	365,602	19,718
Charitable Contributions	136	127
Stock Option Expense	75,590	28,212
Restricted Stock Unit	12,929	10,665
Deferred Revenue		865,747
Net Operating Losses	6,406,223	5,361,500
Org Costs	72,455
Investment in HRCFG INVO, LLC	81,234
Equity in earnings - Positib	3,765
Gross deferred tax assets	7,168,886	6,506,815
Fixed Assets	(26,907)	(32,159)
ROU Lease (ASC 842)	(353,551)	(19,228)
Trademark Amortization	(4,309)	(1,529)
Convertible Note Interest Expense		(42,111)
Note Issuance Cost		(3,855)
Gross deferred tax liability	(384,767)	(98,882)
Less: valuation allowance	(6,785,258)	(6,408,401)
Net deferred tax liability	$ (1,139)	$ (468)

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Operating Loss Carryforwards [Line Items]
Deferred Tax Assets, Valuation Allowance	$ 6,800,000	$ 6,400,000
Deferred tax intangible assets	(1,139)	$ (468)
Operating Loss Carryforwards	25,800,000
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	10,800,000
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration	15,000,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	23,500,000
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	3,500,000
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration	$ 20,000,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Feb. 28, 2022	Jan. 31, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Proceeds from stock issuance			$ 3,650,697
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of stock issued to service	3,000
Subsequent Event [Member] | Paradigm Opportunities Fund LP [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues		94,623
Proceeds from stock issuance		$ 315,000
Consultants and Directors [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Number of stock issued to service		62,528